688238 和元生物
交易中 02-27 14:06:18
资讯
新帖
简况
和元生物（688238）披露2025年度业绩快报，2月26日股价下跌1.46%
证券之星 · 02-26 22:49
和元生物（688238）披露2025年度业绩快报，2月26日股价下跌1.46%
和元生物(688238.SH)2025年度归母净亏损2.21亿元
智通财经 · 02-26 21:08
和元生物(688238.SH)2025年度归母净亏损2.21亿元
和元生物（688238）披露拟设立5亿元产业并购基金并变更公司名称，2月24日股价上涨2.68%
证券之星 · 02-24 18:12
和元生物（688238）披露拟设立5亿元产业并购基金并变更公司名称，2月24日股价上涨2.68%
每周股票复盘：和元生物（688238）拟参设5亿元产业并购基金
证券之星 · 02-15
每周股票复盘：和元生物（688238）拟参设5亿元产业并购基金
每周股票复盘：和元生物（688238）拟更名并参设5亿元产业基金
证券之星 · 02-08
每周股票复盘：和元生物（688238）拟更名并参设5亿元产业基金
和元生物（688238）披露关于变更公司名称、修订《公司章程》并办理工商变更登记的议案，2月5日股价下跌1.55%
证券之星 · 02-05
和元生物（688238）披露关于变更公司名称、修订《公司章程》并办理工商变更登记的议案，2月5日股价下跌1.55%
健康之路携手和元生物精准卡位细胞治疗赛道
证券日报网 · 02-04
健康之路携手和元生物精准卡位细胞治疗赛道
每周股票复盘：和元生物（688238）预计2025年净亏损1.95亿至2.37亿元
证券之星 · 02-01
每周股票复盘：和元生物（688238）预计2025年净亏损1.95亿至2.37亿元
和元生物（688238）披露2025年年度业绩预亏公告，1月27日股价下跌1.17%
证券之星 · 01-27
和元生物（688238）披露2025年年度业绩预亏公告，1月27日股价下跌1.17%
和元生物(688238.SH)发预亏，预计2025年归母净亏损1.95亿元-2.37亿元
智通财经 · 01-27
和元生物(688238.SH)发预亏，预计2025年归母净亏损1.95亿元-2.37亿元
每周股票复盘：和元生物（688238）总经理变更，潘俊屹接任
证券之星 · 01-02
每周股票复盘：和元生物（688238）总经理变更，潘俊屹接任
和元生物（688238）披露公司总经理变更公告，12月31日股价上涨0.45%
证券之星 · 2025-12-31
和元生物（688238）披露公司总经理变更公告，12月31日股价上涨0.45%
机构密集调研存储芯片！券商展望2026年：科技或仍是最强主线
券商中国 · 2025-12-12
机构密集调研存储芯片！券商展望2026年：科技或仍是最强主线
和元生物（688238）新增【基因编辑】概念
证券之星 · 2025-11-17
和元生物（688238）新增【基因编辑】概念
每周股票复盘：和元生物（688238）补选杨兴林为非独立董事
证券之星 · 2025-11-16
每周股票复盘：和元生物（688238）补选杨兴林为非独立董事
和元生物（688238）披露补选董事会成员及变更独立董事公告，11月13日股价上涨1.56%
证券之星 · 2025-11-13
和元生物（688238）披露补选董事会成员及变更独立董事公告，11月13日股价上涨1.56%
每周股票复盘：和元生物（688238）将补选董事及独董
证券之星 · 2025-11-09
每周股票复盘：和元生物（688238）将补选董事及独董
【机构调研记录】南华基金调研和元生物
证券之星 · 2025-11-06
【机构调研记录】南华基金调研和元生物
【私募调研记录】域秀资产调研赛恩斯、和元生物
证券之星 · 2025-11-06
【私募调研记录】域秀资产调研赛恩斯、和元生物
和元生物（688238）披露拟补选非独立董事及变更独立董事事项，11月04日股价下跌3.98%
证券之星 · 2025-11-04
和元生物（688238）披露拟补选非独立董事及变更独立董事事项，11月04日股价下跌3.98%
加载更多
公司概况
公司名称：
和元生物技术(上海)股份有限公司
所属行业：
研究和试验发展
上市日期：
2022-03-22
主营业务：
和元生物技术(上海)股份有限公司的主营业务是细胞和基因治疗CRO/CDMO业务。公司的主要产品是基因治疗载体研制服务、基因功能研究服务、基因检测服务、新药Pre-IND服务、新药Post-IND服务、临床III期生产服务、商业化生产服务、Post-IND配套服务、再生医学制备服务、细胞存储及配套服务、生物原料、生物制剂产品、试剂、试剂盒及其他产品。
发行价格：
13.23
{"stockData":{"symbol":"688238","market":"SH","secType":"STK","nameCN":"和元生物","latestPrice":7.45,"timestamp":1772172378000,"preClose":7.4,"halted":0,"volume":4935128,"delay":0,"changeRate":0.0068,"floatShares":641000000,"shares":649000000,"eps":-0.4533,"marketStatus":"交易中","change":0.05,"latestTime":"02-27 14:06:18","open":7.4,"high":7.5,"low":7.34,"amount":36662100,"amplitude":0.0216,"askPrice":7.45,"askSize":426,"bidPrice":7.44,"bidSize":263,"shortable":0,"etf":0,"ttmEps":-0.4533,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772175600000},"marketStatusCode":2,"adr":0,"adjPreClose":7.4,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":8.14,"lowLimit":6.66,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":649036700,"isCdr":false,"pbRate":3.24,"roa":"--","roe":"--","epsLYR":-0.497,"committee":-0.121966,"marketValue":4835000000,"turnoverRate":0.0077,"status":0,"floatMarketCap":4777000000},"requestUrl":"/m/hq/s/688238","defaultTab":"news","newsList":[{"id":"2614023935","title":"和元生物（688238）披露2025年度业绩快报，2月26日股价下跌1.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614023935","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614023935?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:49","pubTimestamp":1772117352,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，和元生物报收于7.4元，较前一交易日下跌1.46%，最新总市值为48.03亿元。该股当日开盘7.5元，最高7.6元，最低7.34元，成交额达5446.64万元，换手率为1.15%。近日，和元生物发布2025年度业绩快报，营业总收入26,766.34万元，同比增长7.86%；归属于母公司所有者的净利润为-22,071.57万元，较上年同期减少亏损10,109.73万元。期末总资产210,451.45万元，较期初下降7.89%；归属于母公司的所有者权益142,247.66万元，较期初下降18.24%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2614442150","title":"和元生物(688238.SH)2025年度归母净亏损2.21亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614442150","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614442150?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:08","pubTimestamp":1772111325,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和元生物(688238.SH)发布2025年度业绩快报，报告期内，公司实现营业收入2.68亿元，较上年同期增长7.86%;实现归属于母公司所有者的净亏损2.21亿元。报告期内，国内生物医药领域机遇与挑战交织并存，呈现出多元化发展与市场激烈竞争的复杂态势，公司坚持聚焦细胞和基因治疗CRO/CDMO主营业务，并借助国家及行业发展政策，积极战略布局再生医学应用领域。在运营策略上，公司报告期内侧重点在加强客户资源储备、提升品牌影响力以及推动行业发展等方面，以练好内功、升级运营管理能力、推动降本增效为主要绩效目标，逐步提升管理质量和运营效率，为业务后续发展打下坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"和元生物(688238.SH)2025年度归母净亏损2.21亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2613792396","title":"和元生物（688238）披露拟设立5亿元产业并购基金并变更公司名称，2月24日股价上涨2.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613792396","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613792396?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:12","pubTimestamp":1771927971,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，和元生物报收于7.28元，较前一交易日上涨2.68%，最新总市值为47.25亿元。该股当日开盘7.13元，最高7.42元，最低7.04元，成交额达7470.12万元，换手率为1.61%。近日，和元生物披露《2026年第一次临时股东会会议资料》。公告显示，公司拟与上海弘盛君浩股权投资基金管理有限公司及其他合伙人共同设立总规模5亿元的产业并购基金，公司作为有限合伙人认缴出资不超过1亿元，占基金规模约20%，资金来源为自有资金，分期实缴。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400034840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2611434141","title":"每周股票复盘：和元生物（688238）拟参设5亿元产业并购基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2611434141","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611434141?lang=zh_cn&edition=full","pubTime":"2026-02-15 01:40","pubTimestamp":1771090831,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，和元生物报收于7.09元，较上周的7.05元上涨0.57%。本周，和元生物2月9日盘中最高价报7.47元。本周关注点公司公告汇总：和元生物拟参设总规模5亿元的产业并购基金，公司认缴出资不超1亿元。公司公告汇总和元生物拟与上海弘盛君浩股权投资基金管理有限公司及其他合伙人共同设立总规模5亿元的产业并购基金，公司作为有限合伙人认缴出资不超过1亿元，占基金规模约20%，资金来源为自有资金，分期实缴。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2609526182","title":"每周股票复盘：和元生物（688238）拟更名并参设5亿元产业基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2609526182","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609526182?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:59","pubTimestamp":1770490747,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，和元生物报收于7.05元，较上周的7.07元下跌0.28%。本周，和元生物2月2日盘中最高价报7.28元。公司公告汇总：公司拟参与设立5亿元规模的产业并购基金，自身出资不超过1亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2609011253","title":"和元生物（688238）披露关于变更公司名称、修订《公司章程》并办理工商变更登记的议案，2月5日股价下跌1.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609011253","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609011253?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:43","pubTimestamp":1770302593,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，和元生物报收于6.97元，较前一交易日下跌1.55%，最新总市值为45.24亿元。该股当日开盘7.06元，最高7.12元，最低6.95元，成交额达4555.96万元，换手率为1.01%。近日，和元生物技术（上海）股份有限公司发布《关于召开2026年第一次临时股东会的通知》，宣布将于2026年2月26日召开2026年第一次临时股东会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2608369681","title":"健康之路携手和元生物精准卡位细胞治疗赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2608369681","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608369681?lang=zh_cn&edition=full","pubTime":"2026-02-04 20:09","pubTimestamp":1770206940,"startTime":"0","endTime":"0","summary":"本报讯(记者矫月)近日，健康之路股份有限公司(以下简称“健康之路”)与和元生物技术(上海)股份有限公司(以下简称“和元生物”)达成战略合作，正式进军细胞治疗领域。业内人士分析，此举标志 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260204/c674556260.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260204/c674556260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2608907752","title":"每周股票复盘：和元生物（688238）预计2025年净亏损1.95亿至2.37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608907752","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608907752?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:44","pubTimestamp":1769885052,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，和元生物报收于7.07元，较上周的7.74元下跌8.66%。本周，和元生物1月26日盘中最高价报7.85元。本周关注点业绩披露要点：和元生物预计2025年归属净利润亏损1.95亿元至2.37亿元。和元生物预计2025年全年扣非后净利润亏损2.01亿元至2.44亿元。公司公告汇总和元生物预计2025年年度归属于母公司所有者的净利润为-23,700.00万元至-19,500.00万元，较上年同期减亏8,481.30万元到12,681.30万元；扣除非经常性损益的净利润为-24,400.00万元到-20,100.00万元，同比减亏9,191.24万元至13,491.24万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2606093202","title":"和元生物（688238）披露2025年年度业绩预亏公告，1月27日股价下跌1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606093202","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606093202?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:32","pubTimestamp":1769506371,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，和元生物报收于7.61元，较前一交易日下跌1.17%，最新总市值为49.39亿元。该股当日开盘7.69元，最高7.7元，最低7.36元，成交额达8229.16万元，换手率为1.71%。近日，公司披露《2025年年度业绩预亏公告》。公告显示，和元生物预计2025年年度归属于母公司所有者的净利润为-23,700.00万元至-19,500.00万元，较上年同期减亏8,481.30万元到12,681.30万元；扣除非经常性损益的净利润为-24,400.00万元到-20,100.00万元，同比减亏9,191.24万元至13,491.24万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700029722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2606320258","title":"和元生物(688238.SH)发预亏，预计2025年归母净亏损1.95亿元-2.37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606320258","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606320258?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:17","pubTimestamp":1769505429,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和元生物(688238.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润将出现亏损，预计归属于母公司所有者的净利润为-2.37亿元至-1.95亿元，比上年同期亏损减少8481.30万元到12,681.30万元，减亏幅度26.35%到39.41%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"和元生物(688238.SH)发预亏，预计2025年归母净亏损1.95亿元-2.37亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2600039297","title":"每周股票复盘：和元生物（688238）总经理变更，潘俊屹接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2600039297","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600039297?lang=zh_cn&edition=full","pubTime":"2026-01-02 04:28","pubTimestamp":1767299292,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，和元生物报收于6.68元，较上周的6.87元下跌2.77%。本周，和元生物12月22日盘中最高价报6.94元。同日，公司召开第四届董事会第五次会议，审议通过聘任潘俊屹先生为公司总经理，任期至第四届董事会任期届满。潘俊屹先生现任公司董事、再生医学事业部总经理，此前曾任副总经理，具备相关任职资格。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2595778029","title":"和元生物（688238）披露公司总经理变更公告，12月31日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595778029","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595778029?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:16","pubTimestamp":1767176195,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，和元生物报收于6.66元，较前一交易日上涨0.45%，最新总市值为43.23亿元。该股当日开盘6.62元，最高6.7元，最低6.59元，成交额达2903.42万元，换手率为0.68%。同日，公司召开第四届董事会第五次会议，审议通过聘任潘俊屹先生为公司总经理，任期至第四届董事会任期届满。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100034208.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2590527403","title":"机构密集调研存储芯片！券商展望2026年：科技或仍是最强主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2590527403","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590527403?lang=zh_cn&edition=full","pubTime":"2025-12-12 13:25","pubTimestamp":1765517100,"startTime":"0","endTime":"0","summary":" 12月以来，A股市场机构调研活动持续活跃，券商分析师作为调研主力，也在积极进行上市公司的实地走访与交流，挖掘年末布局的方向。 Choice数据显示，本月以来已有超过200家A股上市公司接受了券商调研，电子、机械设备等行业热度高，同时，近期受到热捧的存储芯片概念相关公司被券商密集调研。 临近年末，国金证券、中泰证券等多家券商在本周发布2026年度策略。券商普遍认为，科技板块仍是最看好的明年主线之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2025-12-12/doc-inhapmrm5729848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688238","BK0220","LU0469268626.HKD","BK0148","BK0221","BK0259","688048","605488","301308","BK0216","SGXZ81163826.USD","002353","600487","600814","301468","BK0077","BK0231","301087","BK0209","BK0143","SINA","BK0070","BK0176","SGXZ49509284.SGD","LU1808992512.USD","BK0170","688372","BK0188","LU2328871848.SGD","BK0251","BK0093","BK0224","LU1934453819.USD","LU1969619763.USD","BK0197","BK0005","BK0196","BK0187","BK0214","301319","BK0167","BK0175","300476","688028","BK0144","LU1979443071.USD","688691","002975"],"gpt_icon":0},{"id":"2584482836","title":"和元生物（688238）新增【基因编辑】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2584482836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584482836?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:27","pubTimestamp":1763368074,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，11月17日和元生物新增概念。和元生物主营业务：专注于为基因治疗的基础研究提供基因治疗载体研制、基因功能研究等CRO服务,以及为基因药物的研发提供IND-CMC药学研究、临床样品GMP生产等CDMO服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700020691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2583343654","title":"每周股票复盘：和元生物（688238）补选杨兴林为非独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2583343654","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583343654?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:28","pubTimestamp":1763238492,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，和元生物报收于7.94元，较上周的7.37元上涨7.73%。本周关注点公司公告汇总：和元生物2025年第四次临时股东会选举杨兴林为非独立董事、计小青为独立董事。和元生物于2025年11月13日召开2025年第四次临时股东会，审议通过补选第四届董事会非独立董事及变更独立董事的议案。杨兴林当选为非独立董事，计小青当选为独立董事。出席会议股东64名，代表表决权27.4322%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0216"],"gpt_icon":0},{"id":"2583591165","title":"和元生物（688238）披露补选董事会成员及变更独立董事公告，11月13日股价上涨1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583591165","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583591165?lang=zh_cn&edition=full","pubTime":"2025-11-13 23:00","pubTimestamp":1763046041,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，和元生物报收于7.82元，较前一交易日上涨1.56%，最新总市值为50.75亿元。该股当日开盘7.75元，最高7.83元，最低7.54元，成交额达1.54亿元，换手率为3.13%。公司近日发布公告称，于2025年11月13日召开2025年第四次临时股东会，审议通过了补选第四届董事会非独立董事及变更独立董事的议案。公告显示，杨兴林当选为公司非独立董事，计小青当选为独立董事。出席会议的股东共64名，代表表决权股份总数占公司有表决权股份总数的27.4322%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2582861123","title":"每周股票复盘：和元生物（688238）将补选董事及独董","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861123","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861123?lang=zh_cn&edition=full","pubTime":"2025-11-09 04:00","pubTimestamp":1762632029,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，和元生物报收于7.37元，较上周的7.49元下跌1.6%。本周关注点公司公告汇总：和元生物将补选第四届董事会非独立董事及更换独立董事。公司公告汇总和元生物技术（上海）股份有限公司将于2025年11月13日召开第四次临时股东会，审议补选第四届董事会非独立董事及变更独立董事事项。王富杰因个人身体健康原因辞去非独立董事及审计委员会委员职务，董事会提名杨兴林为非独立董事候选人，任期至第四届董事会任期届满。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2581081559","title":"【机构调研记录】南华基金调研和元生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581081559?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:05","pubTimestamp":1762387515,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月5日披露的机构调研信息，南华基金近期对1家上市公司进行了调研，相关名单如下：1）和元生物 个股亮点：公司依托生成式AI赋能序列设计创新，构建了基于Transformer、Diffusion等深度学习框架的序列评分和序列生成的AI模型南华基金成立于2016年，截至目前，资产管理规模217.23亿元，排名120/211；资产管理规模217.23亿元，排名101/211；管理公募基金数36只，排名116/211；旗下公募基金经理9人，排名112/211。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600004937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0},{"id":"2581081560","title":"【私募调研记录】域秀资产调研赛恩斯、和元生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2581081560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581081560?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:04","pubTimestamp":1762387490,"startTime":"0","endTime":"0","summary":"根据市场公开信息及11月5日披露的机构调研信息，知名私募域秀资产近期对2家上市公司进行了调研，相关名单如下：1）赛恩斯 调研纪要：2025年前三季度公司营收约6.77亿元，同比增长15.81%，扣非净利润7196万元，同比下降10.78%。福建龙立化学2024年营收约1.5亿元，净利润约3800万元，经营符合预期。毛利率与净利率下降主要因费用增长及坏账计提增加。域秀资本致力于为客户提供多策略、优质的资产管理方案，持续为客户创造最大价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025110600004906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688238","BK0218","BK0216","688480"],"gpt_icon":0},{"id":"2580582667","title":"和元生物（688238）披露拟补选非独立董事及变更独立董事事项，11月04日股价下跌3.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580582667","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580582667?lang=zh_cn&edition=full","pubTime":"2025-11-04 22:32","pubTimestamp":1762266746,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘，和元生物报收于7.47元，较前一交易日下跌3.98%，最新总市值为48.48亿元。该股当日开盘7.77元，最高7.8元，最低7.43元，成交额达1.19亿元，换手率为2.45%。近日，和元生物技术（上海）股份有限公司发布公告称，公司将于2025年11月13日召开第四次临时股东会，审议补选第四届董事会非独立董事及变更独立董事事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400039625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688238"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772172390217,"stockEarnings":[{"period":"1week","weight":0.0437},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.0235},{"period":"6month","weight":-0.0476},{"period":"1year","weight":0.3285},{"period":"ytd","weight":0.1111}],"compareEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0664},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.2267},{"period":"ytd","weight":0.0448}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"和元生物技术(上海)股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"14047人(较上一季度增加11.44%)","perCapita":"45642股","listingDate":"2022-03-22","address":"上海市浦东新区国际医学园区紫萍路908弄19号楼","registeredCapital":"64903万元","survey":" 和元生物技术(上海)股份有限公司的主营业务是细胞和基因治疗CRO/CDMO业务。公司的主要产品是基因治疗载体研制服务、基因功能研究服务、基因检测服务、新药Pre-IND服务、新药Post-IND服务、临床III期生产服务、商业化生产服务、Post-IND配套服务、再生医学制备服务、细胞存储及配套服务、生物原料、生物制剂产品、试剂、试剂盒及其他产品。","listedPrice":13.23},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和元生物(688238)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和元生物(688238)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和元生物,688238,和元生物股票,和元生物股票老虎,和元生物股票老虎国际,和元生物行情,和元生物股票行情,和元生物股价,和元生物股市,和元生物股票价格,和元生物股票交易,和元生物股票购买,和元生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和元生物(688238)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和元生物(688238)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}